Author: AbbVie

HCM & HRIS

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

February 20, 2026
AbbVie
No Comments

First all-oral, fixed-duration combination regimen approved for previously untreated patients withCLL Approval supported by data from…